Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors

NCT04278144 is registered in ClinicalTrials.gov with Bolt Biotherapeutics, Inc. as lead sponsor.

NCT NCT04278144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04278144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors
Lead sponsor
Bolt Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 24, 2020
Completion date
February 14, 2025
Enrollment
175 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer, her2-positive colorectal cancer, her2-positive endometrial cancer, her2-positive gastroesophageal cancer, her2-positive solid tumors